Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

NCT00172107 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00172107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00172107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Lead sponsor
Shire
Phase
Phase 2
Overall status
Completed
Start date
May 18, 1995
Completion date
March 24, 1997
Enrollment
217 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis